Product Description
Mechanisms of Action: HSP90 Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Madrigal
Company Location: WEST CONSHOHOCKEN PA 19428
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, France, Germany, Italy
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EUDARIO | P2 |
Completed |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2023-09-01 |